Physician profile

Nicholas Roy

Critical Care Medicine (Internal Medicine) · Cherry Hill, NJ

NPI 1619288073

$7,084.58

in general payments reported to CMS, 2019-2025

38 companies · $1,930 in 2025

The $1,930 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,144.83
Education$157.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,541.27 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals LP $1,395.69 2019-2025 Fasenra, Tezspire, Breztri
Regeneron Healthcare Solutions, INC. $640.01 2019-2025 Dupixent
Genzyme Corporation $620.47 2019-2025
Amgen INC. $331.76 2022-2025 Tezspire
Boehringer Ingelheim Pharmaceuticals, INC. $313.71 2019-2025 Stiolto Respimat, Spiriva Respimat, Ofev
Sanofi-Aventis U.S. LLC $234.97 2022-2025
Insmed, INC. $234.76 2022-2025 Arikayce, Brinsupri
Mylan Specialty L.P. $216.31 2019-2024 Yupelri
Philips North America LLC $204.79 2019-2025 (Ak6) Vest Therapy, Vest Therapy Und
Grifols USA, LLC $133.02 2022-2025 Prolastin-C Liquid
Genentech USA, INC. $131.15 2019-2024 Xolair
Electromed, INC. $130.48 2019-2025 Smartvest
Actelion Pharmaceuticals US, INC. $117.47 2019-2025 Uptravi, Opsumit
Takeda Pharmaceuticals U.S.A., INC. $115.35 2023-2025 Aralast
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Verona Pharma, INC. $107.05 2025 Ohtuvayre
Baxter Healthcare $83.67 2023-2025 Hillrom - Life 2000 Ventilation System
Novartis Pharmaceuticals Corporation $69.68 2019-2023
United Therapeutics Corporation $46.66 2021-2025 Tyvaso, Tyvaso
Jazz Pharmaceuticals INC. $45.48 2022-2025
Teva Pharmaceuticals USA, INC. $39.45 2021-2022
Ani Pharmaceuticals, INC. $39.43 2025 Purified Cortrophin Gel
Azurity Pharmaceuticals, INC. $34.59 2024-2025 Alvesco, Horizant
Resmed Corp $34.36 2019-2024
Advanced Respiratory, INC $26.39 2020
Phadia US INC. $18.70 2025 Immunocap
Harmony Biosciences LLC $18.23 2025
Inogen, INC. $16.76 2023 Inogen One G5 Oxygen Concentrator - Bluetooth
Axsome Therapeutics, INC. $16.41 2024 Sunosi
Pulmonx Corporation $16.20 2022
Viatris Specialty LLC $16.04 2025 Yupelri
Lilly USA, LLC $14.99 2025 Zepbound
Pharming Healthcare, INC. $14.96 2023 Ruconest
Idorsia Pharmaceuticals US INC $13.68 2022
Sunovion Pharmaceuticals INC. $13.32 2019
Mallinckrodt Enterprises LLC $13.02 2019
Circassia INC. $12.46 2019
Bayer Healthcare Pharmaceuticals INC. $11.84 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nicholas Roy

$7,084.58

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,930 reported for 2025 was more than what 86% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).

https://glasscript.com/doctor/1388836/nicholas-roy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.